LONDON, April 20 (Reuters) - Results of a key study comparing Roche (ROG.VX) and Novartis’s (NOVN.VX) eye treatment Lucentis with low doses of cancer drug Avastin will, as predicted, be presented at the ARVO medical meeting on May 1.
LONDON, April 20 (Reuters) - Results of a key study comparing Roche (ROG.VX) and Novartis’s (NOVN.VX) eye treatment Lucentis with low doses of cancer drug Avastin will, as predicted, be presented at the ARVO medical meeting on May 1.
